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ATTENUATION OF CONTACT SENSITIZATION IN MAN*
EDMUND D. LOWNEY, Pzz.D., M.D.t
The clinical severity of allergic contact
dermatitis varies greatly from patient to
patient. Some cases require hospitalization;
others require virtually no treatment. This
variation in degree of dermatitis depends on
two self-evident factors:
A. The amount of sensitizer eliciting the der-
matitis in a previously sensitized patient.
B. The degree or intensity of the reaction of
the patient to a given amount of the sensi-
tizer.
Thus, a small amount of sensitizer may pro-
duce a severe dermatitis in an exquisitely
sensitive patient, while a patient with a low
degree of sensitivity may exhibit only a mild
dermatitis when exposed to a relatively large
amount of the allergen.
The intensity of sensitivity which the pa-
tient manifests clinically may in turn be in-
fluenced by a number of factors:
1. Those which are intrinsic to the patient
such as age, immunological competence and
efficiency of barriers to absorption.
2. Those which are intrinsic to the sensi-
tizer. Some sensitizers may characteristically
induce a stronger sensitivity than others.
3. The method in which the patient was
initially sensitized to the compound may de-
termine whether a strong or weak sensitivity
is produced.
We shall present evidence that the method
of sensitization is of considerable significance
in determining the intensity of allergic con-
tact sensitivity.
Although much is known about the in-
fluence of various methods of sensitization on
the incidence of experimental contact sensi-
tivity in human subjects (1), little is known
about the influence of the method of sensiti-
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zation on the degree of sensitivity which re-
sults. There are at least two exceptions to this
generalization: Epstein, Kligman, and Senecal
(2) have reported that human subjects sensi-
tized to p-nitrosodimethylaniline (NDMA)
injected into abdominal skin developed less
intense sensitivity than did subjects given a
similar injection in the skin of the arm, and
Kligman (1) reports that a more intense
sensitivity to several sensitizers resulted when
the sensitizing dose was divided between
both arms, rather than limited to one arm.
Recent studies of contact sensitivity in the
guinea pig (3) show that this animal readily
develops unresponsiveness to contact sensi-
tizers, so that a weakly sensitized animal of-
ten cannot be made more sensitive by extreme
measures which would induce quite intense
sensitivity in a newly exposed control ani-
mal. In order to demonstrate a similar unre-
sponsiveness in man, we must first devise
methods for inducing weak and strong sensi-
tivity in human subjects. Such a method is
described below.
MATERIAL AND MaTnons
Sensitizing ogent: The sensitizer used was dini-
trochlorobenzene (DNCB). lYe feel that this com-
pound is safe to use as an experimental sensitizer
since it is seldom encountered in industrial or do-
mestic environments. Although it has been sug-
gested that DNCB may cross-react with eblor-
amphenicol (4), Palacios et al. found no evidence
for such cross-reactivity when humans and guinea
pigs sensitized to DNCB were tested epicutane-
ously with chloramphenicol (5). Before beginning
the present study, we ascertained that guinea pigs
made highly sensitive to DNCB show no evidence
of allergic reaction to either intradermal or topi-
cal skin tests with ehloramphenicol (6). Subse-
quently, 29 subjects of the present study who had
been sensitized to DNCB were given occluded
epicutaneous tests with 1% chloramphenicol
cream; none of these subjects showed evidence of
cross-sensitivity to chlorampbenicol.
Subjects: Ninety-six white males served as sub-jects. The great majority consisted of students
under 30 years of age.
Methods of sensitizotion: Subjects were exposed
to DNCB in 7 different ways. In all eases, DNCB,
dissolved in acetone, was applied to disc-shaped
areas of skin demarcated in ink.
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Group 1. (Rapidly sensitized group) Sixteen
subjects were sensitized by 2—4 applications of at
least 1,0007 DNCB each. These subjects, all of
whom were sensitized equivalently, were divided
into subgroups as follows: 1,000 y DNCB was ap-
plied simultaneously to each of 3 extremities (ex-
cluding the right arm) of 8 subjects, and to each
of all 4 extremities of 2 subjects; 2,000 ' DNCB
was applied to each leg of 2 subjects; in the last
4 subjects 2,000 y was applied to one extremity,
followed by a second application of 1,500 DNCB
48 hours later. In all 16 subjects, the circular sites
of application were 3.5 cm. in diameter.
In the remaining groups (except where spe-
cifically stated in groups 4 and 7), all sensitizing
apphcations consisted of 507 DNCB apphed in
0.2% acetone solution to a standard circle 1 cm in
diameter.
Group 2. Seventeen subjects were given weekly
applications of 1007 DNCB to each arm and leg
(i.e., 50 was apphed to 2 standard circles on each
extremity each week.) One subject not sensitized
by 8 weekly applications was given 4 applications
of 507 DNCB (2007) to each extremity on the
ninth week.
Group 3. Twelve subjects were given periodic
applications of 507 DNCB to each of 8 sites (400
total) distributed over the body as follows: one on
each extremity, and one each on the abdomen,
chest, upper back and lower back. Six of these
subjects received weekly applications, while the
other 6 were exposed every third week for 4 visits,
and weekly thereafter.
Group 4. Sixteen subjects were initially given
24—40 applications of 50 DNCB each, widely dis-
tributed over the same 8 areas as in group 3. Sub-
sequently, those subjects not sensitized were given
8—16 applications of 507 DNCB, similarly dis-
tributed, at 3-week intervals until a total epicu-
taneous dose of 3,2007 had been given. In the
case of 6 subjects, applications were made to large
circles, 5.5 cm in diameter, rather than to the
standard 1 cm circle.
Group 5. Eleven subjects were given a single
apphcation of 50 DNCB to the right upper arm
each week.
Group 6. ("Rotaters") Twenty-three subjects
were given identical weekly applications of DNCB
to one extremity but to a different extremity each
week. The amount applied each week was SOy in
19 cases, and 200 y (507 to each of 4 circles) in 4
cases. Subjects not sensitized by 12 weekly ex-
posures of 50 y were then given 4 weekly exposures(one rotation around the 4 extremities) to 1007
followed by 4 weekly apphcations of 150 y.
Group 7. (Mucosal application) Two subjects
were given 200y DNCB weekly, in 02% acetone
solution, applied alternately to the right or left
buccal mucosa. As neither subject had been sensi-
tized after 15 weeks (3,000 7 given), they were
then begun on a program of weekly epicutaneous
applications to the four extremities, on a schedule
identical to that of group 2.
In order to avoid climatic effects on epicutane-
ous tests, treatment of gradually sensitized sub-jects was begun in the early fall, while the more
rapidly sensitized subjects (Group 1) were sensi-
tized several months later; thus most of our sub-
jects in all groups were tested in the same winter
months. This precaution was probably not neces-
sary, for, to our surprise, analysis of all test results
shows virtually no relation to the month in which
testing was carried out.
Determination of rate of sen.sitization: The oc-
currence of sensitization was inferred when the
subject for the first time showed a dermatitic reac-
tion to the standard application of 507 DNGB.
The number of apphcations required to sensitize
is defined as the number of apphcations of sensi-
tizer preceding the first application which elicited
a reaction. (E.g., if a subject developed typical re-
actions to the fifth weekly application of 100 'y
DNCB to each extremity, four applications had
been required to sensitize.)
Measurement of sensitivity: The intensity of
sensitivity was measured by graded series of epi-
cutaneous tests, consisting of application of the
following quantities of DNCB in acetonic solu-
tion to circles 1 cm in diameter: 50 y, 25 y, 107, 5 y,
2 y, 1 y, .4 y, .2 y, .08 y, .04 y, .016 y. This series was
applied twice to all subjects, and many subjects
were also given a third test; these tests are de-
scribed below.
1. First open test: The above series was applied
without occlusion to the inner aspect of the right
upper arm, as illustrated in Figure 1. This test was
applied 5—15 days after the development of sensi-
tivity (as indicated by reaction to a standard sensi-
tizing application).
2. Occluded test: The same series was applied
to the inner aspect of the left upper arm, and oc-
cluded with a plastic film (Glad wrap®) which was
left in place for 36 hours. When a high degree of
sensitivity was demonstrated on the first test,
tests with larger amounts of the sensitizer were
omitted from the second test to avoid unnecessary
trauma. The second test series was applied 3 days
after the first test.
3. Second open test: An open series of tests,
identical to the first test, was reapplied 3—6 weeks
after the first test. This test series was given to
only 38 of the 96 subjects.
All tests were read 3 and 7 days after applica-
tion, and were quantitated in two ways:
1. Lowest eliciting dose was determined for each
subject on each test. This was the smallest amount
of DNCB in the test series which elicited a detect-
able erythema.
2. Total score was obtained by adding scores for
each individual test site, which were graded as
follows:
O —No visible reaction
0.5—Detectable erythema
1.0—Erythema over 50% of the test circle
2.0—Erythema and elevation of part of circle,
or erythema of all of circle
3 —Erythema of all of circle with elevation
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Fm. 1. A graded series of epieutaneous tests applied to the right arm 48 hours previously.
Five positive reactions (to 2 'y, 5 'y, 10 'y, 25 y, and 50 'y DNCB) are visible. There is no
visible reaction to tests with 1 y or less. Test reactions were usually annular in appearance,
most probably because of surface tension phenomena acting to depress the rate of evaporation
of acetone near the center of the test site.
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Group l 2
3.5—Erytbema of all of circle with vesicula-
tion
Individual test scores for each test in a test
series were added together, to derive a total score
for each test series. In the test series illustrated
in Figure 1, for example, the scores assigned to the
five positive tests (2 7, 57, 10 , 25 7, and 50 y)
were 0.5, 1.0, 1.5, 2.0, and 3.0 respectively. The totol
score for this test series then was 8.0, while the
lowest eliciting dose was 2 (as the next test, to
1 y, was negative).
RESULTS
Rate of sensitization: When small amounts
of DNCB are applied to the skin each week,
there may be no evidence of sensitization for
some time. Then, after a long latent period,
applications which were previously tolerated
may suddenly begin to elicit a dermatitie re-
action, presumably as some threshold in the
cumulative dose of sensitizer is reached.
The number of applications of DNCB re-
quired to sensitize subjects in each group is
presented in Figure 2.
It should be noted in this figure that all
subjects in Group 1, (who received applica-
tions totalling 3 mgm or more DNCB within
a 48 hour period) were sensitized by this
single treatment, while subjects in all other
groups were sensitized more slowly.
ci.
•0
0
3 4
Fia. 2. Number of applications of DNCB be-
fore appearance of sensitivity. Each dot represents
one subject. Simultaneous applications of DNCB
to several sites are counted as one application.
.4 Denotes median.
o Represents subject eventually exposed to
method of Group 1.
+ Foursubjects in Group 1 received 2 applica-
tions within 48 hours.
>< Subjects not sensitized by 20 weekly applica-
tions, but sensitized later are presented in
"20+" row.
*
"N.S." refers to subjects who were never
sensitized.
++ No subject in group 7 was sensitized by
application of DNCB to buccal mucosa.
The number of applications to skin (by
method of group 2) required to sensitize is
presented.
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The rate at which sensitization appeared
in groups 2—6 was related to a number of
factors which, together with additional evi-
dence, will be analyzed elsewhere.
Intensity of sensitivity., Subjects who were
rapidly sensitized to DNCB by applications
of 1 mgm or more to several sites (Group 1)
developed a more intense degree of sensitivity
than did those sensitized more slowly. This
is illustrated in Figures 3—6.
In Figure 3, minimal eliciting doses on the
first open test series are presented.
Thirty-eight subjects were also given a —
second open test 3—6 weeks after the first test.
Reactions on the second open test (presented
in Figure 4) often reflected an increase in
sensitivity which had occurred during the in-
0•••
2 3 4 5 6 7
Fio. 3. Level of sensitivity as destermined by
first open test series. Each dot denotes the smallest
amount of DNCB eliciting a visible reaction when
applied without occlusion in one subject.
>< Test was scored in "50+" category when test
with 50 y DNCB on right arm showed no reaction,
in spite of mild reaction to sensitizing application
of 50 y DNCB to more sensitive areas. Other
symbols as in Figure 2.
_____r____'t.__Q
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2r FIG. 6. Level of sensitivity as reflected in "total
score" on first open test. This score reflects the
I intensity of each positive reaction as well as the
2 threshold concentration. Score of "0" is equivalentto score of "50+" in Figures 3—5. Symbols as in
57 previous figures.
IOy
257 • terval. However, this rise in sensitivity was
SOy more marked in the rapidly sensitized sub-jects (Group 1) than in gradually sensitized
NS* __________ - ones.
Group I
FIG. 4. Level of sensitivity as reflected in second
open test series. On repetition of open test series
3—6 weeks later, a higher level of sensitivity was
noted in many subjects, especially those in Group
1. Symbols as in Figure 3.
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Ftc. 5. Level of sensitivity as determined by
occluded tests. With occlusion, less DNCB was
needed to elicit reaction, but subjects in Group 1
are still shown to be more sensitive than others.
* Subjects that were not sensitized were not
tested with occlusion. Otherwise, symbols as in
Figure 3.
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2 3 4 5 6 7 The results of occluded tests (presented in
Figure 5) also show that the more rapidly
sensitized subjects were more intensely sensi-
tive.
Total test scores (Fig. 6) tend to magnify
248 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
TABLE I
Group
Number of subjerts Not sensitized by
metbod of:
Own Group Group 2 Group 1
1
2
3
4
5
6
7
Total
0/16
0/17
1/12
10/16
0/11
6/23
2/2
19/96
—
4/10
4/6
1/2
9/18
0/1
2/3*
0/1**
1/1
3/6
* One subject did not complete the last stage of
this experiment.
** Three subjects did not complete the last stage
of this experiment.
the difference in sensitivity between rapidly
and slowly sensitized subjects because the
highly sensitive subjects often exhibited
stronger reactions to all test doses, as well as
detectable reactions to very low doses.
The data presented in each of Figures 3—6
were evaluated separately by means of the
Kruskal-Wallis test, which is analogous to an
analysis of variance but is non-parametric and
uses rank order data. This test showed that
there was less than one chance in a thousand
that all subjects represented in Figures 3 and 4
were from the same population. In the ease of
Figures 5 and 6, this probability was less
than one in a hundred. In addition, Group 1
was shown to differ reliably from the other
6 groups combined (P < .001 for data in
Figures 3—5; P < .01 for data in Figure 6).
EVIDENCE FOR UNRESPONSIVENESS
IN MAN
Nineteen of our subjects failed to develop
detectable sensitivity to DNCB in spite of
administration of as much as 3,000 y of the
compound. Treatment of these subjects is de-
scribed in detail in Table I. Two of these 19
subjects had received 3 mgm. DNCB applied
to the buceal mueosa, a method which was not
expected to sensitize.
It is noteworthy that all of the 17 subjects
who were not sensitized by topical application
of the compound had been given applications
of small amounts of DNCB to multiple body
areas, either simultaneously or in rotation.
As none of these 19 subjects was sensitized
by the originally assigned method of applica-
tion, 18 of them were subsequently treated
according to the schedule of Group 2 (100 y
DNCB was applied to each extremity for 8
weeks, followed by 200 y for a ninth week).
Nine subjects were sensitized by this method,
while 9 were not. Five of these 9 were then
subjected to the treatment of Group 1, con-
sisting of 3 simultaneous applications of 1
mgm DNCB to the left arm and both legs.
(The other 4 subjects unfortunately left the
experiment before this stage could be com-
pleted.) In addition, one subject in Group 3
was subjected to the procedure of Group 1 di-
rectly, without going throngh the Group 2
procedure.
It can be seen from Table I that while
100% of 17 subjects in Group 2 were sensitized
by the method of Group 2, 9 of 18 subjects pre-
viously exposed to DNCB by other methods
were not sensitized by the same method.
Likewise, while 100% of the virgin subjects
in Group 1 were sensitized by the massive
amounts of DNCB to which they were ex-
posed, 3 of 6 subjects previously given pro-
longed topical or mucosal exposures to DNCB
could not be sensitized by the same method.
The other 3 subjects were sensitized by the
method of Group 1, but only to a low degree
(as shown in Fig. 3).
Is this true hypo-responsiveness? Or is it
simply by chance that all of these unresponsive
subjects fell into groups 4, 6, and 7 while
none fell in groups 1 or 2? The experiment is
being repeated on a larger scale to answer this
question.
COMMENT
When very small amounts of DNCB were
applied at weekly intervals, it was not un-
usual for sensitivity to appear suddenly after
an exposure period of several months. This is
in accord with the common clinical observa-
tion of contact dermatitis which is un-
expectedly caused by a substance the patient
had been using "for years". These observa-
tions also show that contact sensitization can
result from a prolonged series of diagnostic
patch tests; in our group subjected to a single
application of 50 y DNCB to the right arm
each week (Group 5), the sensitization rate
was 100%. We have no compelling explana-
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tion of the mechanism by which the "memory"
of previous exposures to the sensitizer is
stored, awaiting the accumulation of a critical
level of total exposure to the chemical before
the final steps in the sensitization process are
triggered into motion.
However, we have also shown that allergic
contact sensitivity is not an all-or-nothing
process, but occurs in all degrees of intensity.
Although we have not analyzed experimentally
all factors which determine the intensity of
sensitivity, there is little doubt that, in our
study, a rapidly induced sensitivity was
usually more severe than a gradually induced
one. Perhaps the initial exposure to a sensi-
tizer sets in motion processes which tend to
inhibit contact sensitivity, as well as those
processes which promote sensitization; and
with exposure to sub-sensitizing doses of the
chemical over a period of time, the in-
hibitory processes come to dominate before
sensitivity can be achieved. There is an ob-
vious telcologic advantage in suppressing con-
tact sensitivity to compounds to which exposure
is chronic or widespread.
Undoubtedly, many of our subjects in whom
very mild sensitivity to DNCB was induced
could have been exposed to dilute solutions of
the chemical with impunity. It is possible
that the development of clinically significant
contact dermatitis can be prevented by a pro-
gram of gradual exposure.
Seven of our subjects never developed a posi-
tive epicutaneous reaction to DNCB. We do
not know if these subjects had no sensitivity,
or if their level of sensitivity was simply too
low to be detected by our methods.
Alter a weak degree of sensitivity has been
induced, will it remain weak indefinitely, or
will it he possible to raise the level of sen-
sitivity to a high level by the later applica-
tion of a more effective sensitization pro-
ccdure? Our preliminary results suggest that
the former is the case, the weakly sensitized
subject being partially unresponsive to at-
tempts to raise his level of sensitivity. But
this conclusion is subject to confirmation.
STJMMAEY
Ninety-six human subj ects were exposed
topically to various amounts of DNCB ac-
cording to a number of schedules, and the in-
tensity of the resulting contact sensitivity
was measured by series of graded cpicutaneous
tests.
Subjects who were rapidly sensitized by
topical apphcation of a large amount of
DNCB tended to develop a higher level of
sensitivity than did subjects who were gradually
sensitized by a series of applications of sub-
sensitizing amounts of the chemical. This differ-
ence was statistically reliable (P = <.001).
Thus, it is possible to manipulate the level of
contact sensitivity which occurs in man by
manipulating the circumstances under which
sensitization is induced.
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